CG Oncology reports FY2025 net loss $161M; cash $903M provides runway to 1H 2029

CG Oncology, Inc.

2025-FY EPS reported -$2.08 revenue$4,040,000

Q4 2025 net loss $41.3M ($0.52/share) vs $31.8M ($0.46/share) in Q4 2024.
Full-year 2025 net loss $161.0M ($2.08/share) vs $88.0M ($1.41/share) in FY2024.
Cash, equivalents, and securities ~$903M as of Feb 26, 2026; funded into first half 2029.
PIVOT-006 Phase 3 topline data in intermediate-risk NMIBC expected 1H 2026.
CORE-008 Cohort CX first combination results with gemcitabine in HR NMIBC expected 1H 2026.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-079452
form_type: 8-K
ticker: CGON
cik: 0001991792
company_name: CG Oncology, Inc.
filed_at: 2026-02-27T23:59:59+00:00
discovered_at: 2026-05-14T18:02:36.944905+00:00
generated_at: 2026-05-15T23:13:39.623062+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-079452
json_url: https://secwatch.observer/filing/0001193125-26-079452.json
markdown_url: https://secwatch.observer/filing/0001193125-26-079452.md
text_url: https://secwatch.observer/filing/0001193125-26-079452.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1991792/000119312526079452/0001193125-26-079452-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1991792/000119312526079452/ck0001991792-20260227.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-079452

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.